Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 116 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hypertrophic Cardiomyopathy (HCM) Clear all
Recruiting Phase 4 Interventional

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

NCT07600177
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Kansas City, Missouri • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional

High Intensity Exercise for Increasing Fitness in Patients With Hypertrophic Cardiomyopathy

NCT03335332
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
High intensity exercise, Moderate intensity exercise
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting No phase listed Observational

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

NCT05489705
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
Mavacamten, Non-mavacamten symptomatic oHCM therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
60
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT05556343
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
MYK-224
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Extended ECG Monitoring in HCM Patients

NCT04056715
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Nonsustained Ventricular Tachycardia, Ventricular Tachycardia, Atrial Fibrillation, Arrhythmia
Interventions
Zio XT
Device
Lead sponsor
iRhythm Technologies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Factors Contributing to Increased Left Ventricle Size in Patients With Abnormally Enlarged Hearts

NCT00001878
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease

NCT00001632
View directory record Official record
Conditions
Healthy, Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy

NCT01150461
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
losartan, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy

NCT00074880
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle

NCT00001960
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Pacemaker therapy
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 1 Interventional

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy

NCT04418297
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic Obstructive
Interventions
CT-G20, Placebo
Drug
Lead sponsor
Celltrion
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of Blood Flow in Heart Muscle

NCT00001631
View directory record Official record
Conditions
Coronary Disease, Healthy, Hypertrophic Cardiomyopathy, Myocardial Ischemia
Interventions
Magnetic resonance imaging
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Not applicable Interventional

Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy

NCT06775886
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy
Interventions
myPACE+ algorithm
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

NCT05362045
View directory record Official record
Conditions
Healthy Participants
Interventions
Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
4
States / cities
Miami, Florida • Springfield, Missouri • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Sep 17, 2026, 4:08 AM EDT
Not yet recruiting Not applicable Interventional

NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices

NCT07806149
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction, Systolic Anterior Motion
Interventions
SESAME Procedure
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Pilot Project Exploring the Impact of Whole Genome Sequencing in Healthcare

NCT01736566
View directory record Official record
Conditions
Healthy Adults (Full Study and Extension Phase), Hypertrophic Cardiomyopathy or Dilated Cardiomyopathy
Interventions
Family History + Whole Genome Sequencing, Family History Only
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease

NCT00001881
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Familial
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
9,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT03442764
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten, Placebo
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
32
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT03470545
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten, Placebo
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting No phase listed Observational

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

NCT06372457
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
Approved Hypertrophic Cardiomyopathy drug treatments, Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

NCT04349072
View directory record Official record
Conditions
HOCM, Hypertrophic Obstructive Cardiomyopathy
Interventions
Mavacamten, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
21
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 4 Interventional Results available

Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve

NCT03249272
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy, Microvascular Ischaemia of Myocardium
Interventions
Regadenoson, Adenosine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

NCT05767346
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
28
States / cities
Anchorage, Alaska • Phoenix, Arizona • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

NCT04848506
View directory record Official record
Conditions
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten (5 - 20 mg)
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
52
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 17, 2026, 4:08 AM EDT